

Thaw and Culture Details


Cell Line Name	ES01
WiCell Lot Number	ES01-DL-01
Parent Material	ES01-MCB-02
Provider	ES Cell International
Banked by	WiCell
Thaw and Culture Recommendations	Thaw 1 vial into 1 well of a 6 well plate. WiCell recommends thawing using ROCK Inhibitor for best results.
Culture Platform	Feeder Dependent
	Medium: hES Medium
	Matrix: MEF
Protocol	WiCell Feeder Dependent Protocol
Passage Number	p86 These cells were cultured for 85 passages prior to freeze. WiCell adds +1 to the passage number at freeze so that the number on the vial best represents the overall passage number of the cells at thaw.
Date Vialed	03-December-2009
Vial Label	ES01-DL-01 P86 KR 03 DEC 2009 SOPCC035D
Biosafety and Use Information	Appropriate biosafety precautions should be followed when working with these cells. The end user is responsible for ensuring that the cells are handled and stored in an appropriate manner. WiCell is not responsible for damages or injuries that may result from the use of these cells. Cells distributed by WiCell are intended for research purposes only and are not intended for use in humans.

Testing Performed by WiCell

Test Description	Test Provider	Test Method	Test Specification	Result
Karyotype by G-banding	WiCell	SOP-CH-003	Expected karyotype	See Report
Post-Thaw Viable Cell Recovery	WiCell	SOP-CH-305	 ≥ 15 Undifferentiated Colonies prior to passage, ≤ 30% Differentiation prior to passage, and recoverable attachment after passage 	Pass
Identity by STR	UW Molecular Diagnostics Laboratory	PowerPlex 1.2 System by Promega	Consistent with STR profile of deposited cell line	Pass
Sterility - Direct transfer method	Apptec	30744	Negative	Pass
Mycoplasma	Bionique	M250	No contamination detected	Pass
Flow Cytometry for ESC Marker Expression	UW Flow Cytometry Laboratory	SOP-CH-101 SOP-CH-102 SOP-CH-103 SOP-CH-105	Report - no specification	See report

©2020 WiCell Research Institute

The material provided under this certificate has been subjected to the tests specified and the results and data described herein are accurate based on WiCell's reasonable knowledge and belief. Appropriate Biosafety Level practices and universal precautions should always be used with this material. For clarity, the foregoing is governed solely by WiCell's Terms and Conditions of Service, which can be found at http://www.wicell.org/privacyandterms.



Date of Lot Release	Quality Assurance Approval
02-March-2010	7/14/2020 X AA
02-101611-2010	AA Quality Assurance Signed by: Arntz, Andy

©2020 WiCell Research Institute

The material provided under this certificate has been subjected to the tests specified and the results and data described herein are accurate based on WiCell's reasonable knowledge and belief. Appropriate Biosafety Level practices and universal precautions should always be used with this material. For clarity, the foregoing is governed solely by WiCell's Terms and Conditions of Service, which can be found at http://www.wicell.org/privacyandterms.



Histocompatibility/Molecular Diagnostics Laboratory

University of Wisconsin Hospital and Clinics

Short Tandem Repeat Analysis*

Sample Report: 0423-STR

UW HLA#: 62515

Sample Date: 02/12/10 Received Date: 02/12/10

Requestor: WiCell Research Institute

Test Date: 02/19/09

File Name: 100220

2

Report Date: 02/22/10

Sample Name: (label on tube) 0423-STR

Description: DNA Extracted by WiCell

241.16 ug/mL; 260/280 = 1.88

Locus	Repeat #	STR Genotype
D16S539	5,8-15	11,11
D7S820	6-14	11,12
D13S317	7-15	8,8
D5S818	7-15	12,13
CSF1PO	6-15	12,12
TPOX	6-13	8,12
Amelogenin	NA	X,X
TH01	5-11	9,9
vWA	11, 13-21	17,17

Comments: Based on the 0423-STR DNA dated and received on 02/12/10 from WiCell, this sample (UW HLA# 62515) matches exactly the STR profile of the human stem cell line ES01 comprising 11 allelic polymorphisms across the 8 STR loci analyzed. No STR polymorphisms other than those corresponding to the human ES01 stem cell line were detected and the concentration of DNA required to achieve an acceptable STR genotype (signal/noise) was equivalent to that required for the standard procedure (~1 ng/amplification reaction) from human genomic DNA. These results suggest that the 0423-STR DNA sample submitted corresponds to the ES01 stem cell line and it was not contaminated with any other human stem cells or a significant amount of mouse feeder layer cells. Sensitivity limits for detection of STR polymorphisms unique to either this or other human stem cell lines is ~5%.

1

Manager HLA/Molecular Diagnostics Laboratory

PhD, Director E HLA/Molecular Diagnostics Laboratory

* Testing to assess engraftment following bone marrow transplantation was accomplished by analysis of human genetic polymorphisms at STR loci. This methodology has not yet been approved by the FDA and is for investigational use only.

This report is confidential. No part may be used for advertising or public announcement without written permission. Results apply only to the sample(s) tested.



Report Number 824974 Page 1 of 1

WiCell Research Institute

December 28, 2009 P.O. #:

STERILITY TEST REPORT

ES01-DL-01, #7536, SA01-DL-02, #7328,

Sample Information:

Date Received: Date in Test: Date Completed: December 08, 2009 December 09, 2009 December 23, 2009

hES Cells

Test Information:

Test Codes: 30744, 30744A Immersion, USP / 21 CFR 610.12 Procedure #: BS210WCR.201

H9 (SYN-GFP)-MCB-02, # 5497

TEST PARAMETERS	TEST PARAMETERS PRO	
Approximate Volume Tested	0.5 mL	0.5 mL
Number Tested	6	6
Type of Media	SCD	FTM
Media Volume	400 mL	400 mL
Incubation Period	14 Days	14 Days
Incubation Temperature	20 °C to 25 °C	30 °C to 35 °C
RESULTS	6 NEGATIVE	6 NEGATIVE

10.00 QA Reviewer Date

Technical Reviewer

-2800 Date

Testing conducted in accordance with current Good Manufacturing Practices.





BIONIQUE[®] TESTING LABORATORIES, INC.

APPENDIX BIONIQUE[®] TESTING LABORATORIES, INC.

Document ID #:	DCF9002E	
Title:	QUALITY ASSURANCE I	REPORT - GMP
Effective Date:	01/04/10	
Edition #:	02	

QUALITY ASSURANCE REPORT - GMP

Test Performed	PROCEDURAL RE	FERENCE	TEST PERF	ORMED	PROCEDURAL REFERENCE	
M-250 M-300 M-350	SOP's 3008, 301 SOP's 3008, 301 SOP's 3008, 301	4	M-700 M-800		SOP's 3008, 3009, 3010 SOP's 3008, 3011, 3016	
Bionique Sample II	D #(s) <u>59987</u>	59988	59989	599	90 59991	

This testing procedure was performed in compliance with the FDA's Current Good Manufacturing Practice (cGMP) standards (to the extent that the regulations pertain to the procedures performed) as specified in the Code of Federal Regulations, Title 21 Parts 210 and 211 [21 CFR 210 & 211]. All related records derived from the test procedures have been reviewed by the Quality Assurance Department. The individual's signature below verifies that the methods and procedures referenced above have been followed and that the Final Report accurately reflects the raw data generated during the course of the procedures. All records, including raw data and final reports are archived on site for a minimum of seven years.

The specified test's procedures determine the intervals at which samples are inspected. The medium used for testing must pass quality control mycoplasmal growth promotion testing and sterility testing. Traceability of all of the components used is assured and supporting documentation can be supplied upon request.

Quality Assurance Review Date: 2/17/10 Reviewed By Rachael Cartier, QA Assistant:

NOTE:

- 1. Prior to receipt at Bionique[®] Testing Laboratories, Inc., the stability of the test article is the responsibility of the company submitting the sample. Bionique Testing Laboratories Inc. will assume responsibility for sample stability following receipt and prior to being placed on test.
- 2. This test is for the detection of microbiological growth and does not require statistical validation.

BIONIQUE[®] TESTING LABORATORIES, INC.

APPENDIX

Document ID #:	DCF9002E
Title:	QUALITY ASSURANCE REPORT - GMP
Effective Date:	05/21/09
Edition #:	02

REFERENCES

Regulatory:

- 1. Department of Health and Human Services, Food and Drug Administration (USA) [FDA]. Code of Federal Regulations [CFR], Title 21 CFR Part 210, Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General. FDA. Office of the Federal Register, National Archives and Records Department.
- Department of Health and Human Services, Food and Drug Administration (USA) [FDA]. Code of Federal Regulations [CFR], Title 21 CFR Part 211, Current Good Manufacturing Practice for Finished Pharmaceuticals. FDA. Office of the Federal Register, National Archives and Records Department.
- 3. Department of Health and Human Services, Food and Drug Administration (USA) [FDA]. Points to Consider in the Characterization of Cell Lines Used to Produce Biologicals, Director, Center for Biologics Evaluation and Research, FDA. May, 1993. Docket No. 84N-0154.
- 4. Department of Health and Human Services, Food and Drug Administration (USA) [FDA]. Code of Federal Regulations [CFR], Title 21 CFR Part 610.30, General Biological Products Standards; Subpart D, Test for Mycoplasma. FDA. Office of the Federal Register, National Archives and Records Department.

General:

- 1. Barile MF, Kern J. Isolation of Mycoplasma arginini from commercial bovine sera and its implication in contaminated cell cultures. Proceedings of the Society for Experimental Biology and Medicine, Volume 138, Number 2, November 1971.
- 2. Chen, T.R. In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Experimental Cell Research, 104: 255-262, 1977.
- 3. Carolyn K. Lincoln and Daniel J. Lundin. Mycoplasma Detection and Control. U. S. Fed. for Culture Collections Newsletter, Vol. 20, Number 4, 1990.
- 4. Fetal Bovine Serum; Proposed Guideline. National Committee For Clinical Laboratory Standards (NCCLS), Vol. 10, Number 6, 1990. (NCCLS publication M25-P).
- 5. McGarrity GJ, Sarama J, Vanaman V. Cell Culture Techniques. ASM News, Vol. 51, No. 4, 1985.
- 6. Tully JG, Razin S. Methods in Mycoplasmology, Volumes I and II. Academic Press, N.Y., 1983.
- 7. Barile MF, Razin S, Tully JG, Whitcomb RF. The Mycoplasmas, Volumes 1-4. Academic Press, N.Y., 1979.
- 8. <u>http://www.bionique.com/</u> Safe Cells Insights



BIONIQUE TESTING LABORATORIES, INC.

APPENDIX IV

Document#: Edition#: Effective Date: Title: DCF3013D 10 07/15/2003 **M-250 FINAL REPORT SHEET**

M-250 FINAL REPORT

Direct Specimen Culture Procedure 3008, 3011, 3013

TO: Wicell QA

BTL SAMPLE ID#: 59988

P.O.#:

DATE REC'D: 01/20/2010

Page 1 of 2

TEST/CONTROL ARTICLE:

ESO1.DL.01.V p89 #0423

LOT#: NA

DIRECT CULTURE	SET-UP (DAY 0)		DATE:	01/20/2010	<u>0</u> aa dha anwesan 2019
INDICATOR	CELL LINE (VERO)	SEE DNA	FLUOROCHRO	ME RECORD SHEET	
					DATE
THIOGLYC	OLLATE BROTH	DAY 7	+	0	01/27/2010
an a		DAY 28	+	\bigcirc	02/17/2010
BROTH-FORTIFIED	COMMERCIAL				
0.5 mL SAMPLE		DAY 7	+	$\overline{\bigcirc}$	01/27/2010
6.0 mL BROTH	and the second	DAY 28	+	0	02/17/2010
BROTH-MODIFIED	HAYFLICK	1			V
0.5 mL SAMPLE		DAY 7	+	\odot	01/27/2010
6.0 mL BROTH		DAY 28	+	\bigcirc	02/17/2010
BROTH-HEART INE	TUSION				(1) (5) Secure for the secure secu
0.5 mL SAMPLE		DAY 7	+	\odot	01/27/2010
6.0 mL BROTH		DAY 28	+	\bigcirc	02/17/2010
Dev.020 0.41.00					

.

(See Reverse)

APPENDIX IV

Document#:	DCF3013	D .			
Edition#:	10				
Effective Date:	07/15/2	003			
Title:	M-250 F	INAL REPORT	SHEET		-
SAMPLE ID#: 59	988		AEROBIC	MICROAEROPHILIC	DATE
AGAR PLATES-FORTI COMMERCIAL	FIED	DAY 7 DAY 14 DAY 21	+ + + 00	+ © + © + ©	01/27/2010 02/03/2010 02/10/2010
AGAR PLATES-MODIF HAYFLICK	IED	DAY 7 DAY 14 DAY 21	+ () + () +	+ (⁽)) + (⁽)) + (⁽))	01/27/2010 02/03/2010 02/10/2010
AGAR PLATES-HEART INFUSION		DAY 7 DAY 14 DAY 21	+ () + () + ()	+ (C) + (O) + (O)	01/27/2010 02/03/2010 02/10/2010
BROTH SUBCULTURES	(DAY 7)		DATE:	01/27/2010	
AGAR PLATES-FORTI COMMERCIAL	FIED	DAY 7 DAY 14 DAY 21	+ () + () + ()	+ (5) + (5) + (5)	02/03/2010 02/10/2010 02/17/2010
AGAR PLATES-MODIF HAYFLICK	IED	DAY 7 DAY 14 DAY 21	+ () + () +	+ (D) + (D) + (D)	02/03/2010 02/10/2010 02/17/2010
AGAR PLATES-HEART INFUSION		DAY 7 DAY 14 DAY 21	+ 0 + 0	+ () + () + ()	02/03/2010 02/10/2010 02/17/2010

RESULTS: No detectable mycoplasmal contamination

2/17/10

1

Laboratory Director Ph.D.

1

M-250 Procedural Summary: The objective of this test is to ascertain whether or not detectable mycoplasmas are present in an <u>in vitro</u> cell culture sample, be it a primary culture, hybridoma, master seed stock or cell line. This procedure combines an indirect DNA staining approach to detect non-cultivable mycoplasmas with a direct culture methodology utilizing three different mycoplasmal media formulations. The indirect approach involves the inoculation of the sample into a mycoplasma-free VERO (ATCC) indicator cell line and performing a DNA fluorochrome assay after 72-120 hours of incubation. The direct culture aspect of the test utilizes three different mycoplasmal media including both broth and agar formulations. The sample is inoculated into each of the 3 broth formulations and also onto duplicate plates (0.1 mL/plate) for each of the 3 agar formulations. Subculture from broth to fresh agar plates is carried out after 7 days incubation. Agar plates are incubated aerobically and microaerophillically in order to detect any colony forming units morphologically indicative of mycoplasmal contamination. Isuance of the final report with signature of the Laboratory Director signifies that the required controls were performed concurrently with the test sample(s) as detailed in the referenced SOPs and that all test conditions have been found to meet the required acceptance criteria for a valid test, including the appropriate results for the positive and negative controls.



TESTING SERVICES

BIONIQUE TESTING LABORATORIES, INC

APPENDIX I		
Document #:	DCF3008A	
Edition #:	06	
Effective date:	9/17/2003	
Title:	DNA FLUOROCHROME ASSAY RESULTS	· .

DNA-FLUOROCHROME ASSAY RESULTS

Procedures 3008, 3009, 3011

Sample ID # <u>59988</u>	<u>M-250</u>	Date Rec'd:	01/2	0/2010	P.O. #
Indicator Cells Inoculated:	Date/Initials:	12110		KG	
Fixation:	Date/Initials:	1/25/10	/	JA	
Staining:	Date/Initials:	1/25/10	/	JA	

TEST/CONTROL ARTICLE:

ESO1.DL.01.V p89 #0423

LOT# NA

Wicell OA

	UOROCHROME A	ADDAT MEDOLID.
X	A reaction with staining limited to the nuclear region, which indicates no mycoplasmal contamination.	
	POSITIVE:	A significant amount of extranuclear staining which strongly suggests mycoplasmal contamination.
	_INCONCLUS	IVE:
	1. 	A significant amount of extranuclear staining consistent with low - level mycoplasmal contamination or nuclear degeneration.
		A significant amount of extranuclear staining consistent with bacterial, fungal or other microbial contaminant or viral CPE. Morphology not consistent for mycoplasmal contamination.
COMMI	ENTS:	

Date: 1/25/10 Results Read by: TA Date of Review: 1/25/10 Reviewed by: SNA



Report Date: February 03, 2010

Case Details:

Cell Line: ES01-DL-01(0423) Passage #: 90 Date Completed: 2/3/2010 Cell Line Gender: Female Investigator: National Stem Cell Bank Specimen: hESC on MEF feeder Date of Sample: 1/27/2010 Tests,Reason for: DL testing Results: 46,XX Completed by , CG(ASCP), on 2/3/2010 Reviewed and interpreted by , PhD, FACMG, on 2/3/2010

Interpretation: No abnormalities were detected at the stated band level of resolution.

Contraction of the International Contractional Contractionan Contractionan Contractional Contractional Contra				e line i	Cell: S01-01 Slide: A-3 Slide Type: Karyotyping
	7 7 14 20	 е с с с с	10 16 22	12 12 18	# of Cells Counted: 20 # of Cells Karyotyped: 4 # of Cells Analyzed: 8 Band Level: 425-550

Results Transmitted by Fax / Email / Post Sent By:_____ QC Review By: _____

Date:	
Sent To:	_
Results Recorded:	_



Procedures performed: SOP-CH-101 SOP-CH-102 SOP-CH-103 SOP-CH-105 Cell Line: ES01-DL-01 Passage Sample ID: 0423-FAC **Date of:** (*mm/dd/yy*) acquisition: 02/11/10 file creation: 02/11/10 file submission: 02/12/10

	SSEA4 -	SSEA4 +	SSEA4 +	SSEA4 -	ALL	ALL
antigen2:	<u>antigen2 +</u>	<u>antigen2 +</u>	<u>antigen2 -</u>	<u>antigen2 -</u>	SSEA4 +	<u>antigen2 +</u>
SSEA3	0.74	81.60	10.10	7.61	91.70	82.34
TRA1-60	0.71	90.20	1.69	7.38	91.89	90.91
TRA1-81	0.83	89.50	2.12	7.60	91.62	90.33
Oct-4	0.72	87.30	5.93	8.00	93.23	88.02
SSEA1	0.34	3.77	88.40	7.51	92.17	4.11

